Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-08
2005-03-08
Weber, Jon P. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C562S553000, C530S331000, C530S332000
Reexamination Certificate
active
06864240
ABSTRACT:
Dipeptide derived inhibitors of the β-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of Aβ peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce Aβ peptide formation and in pharmaceutical compositions.
REFERENCES:
patent: 4709010 (1987-11-01), Holzemann et al.
patent: WO 9730072 (1997-08-01), None
Dominguez D. I., Amyloid 8 (2) 124-42, 2001.*
Wolfe, J. Med. Chem. 44, 2039, 2001.*
Wilkinson, Chem. Eng. News 45-57, 2002.*
Tung Jay S, J. Med. Chem. 45 (2) 259-62, 2002.*
Ghosh A K, J. Med. Chem. 44(18) 2865-8, 2001.*
Turner R. T., Biochemistry 40 (34) 10001-6, 2001.*
Majer, Pavel, et al., “Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors”Protein Science, 6:1458-1466 (1977).
Fang Lawrence
Gailunas Andrea
Guinn Ashley
Hom Roy
John Varghese
Elan Pharmaceuticals Inc.
Lukton David
McDonnell Boehnen & Hulbert & Berghoff LLP
Weber Jon P.
LandOfFree
Dipeptide inhibitors of β-secretase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dipeptide inhibitors of β-secretase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptide inhibitors of β-secretase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3445912